Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

IGC Pharma (IGC) EBITDA (2016 - 2025)

Historic EBITDA for Pharma (IGC) over the last 17 years, with Q3 2025 value amounting to -$1.8 million.

  • Pharma's EBITDA fell 623.56% to -$1.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$6.5 million, marking a year-over-year increase of 4843.64%. This contributed to the annual value of -$7.2 million for FY2025, which is 4513.58% up from last year.
  • According to the latest figures from Q3 2025, Pharma's EBITDA is -$1.8 million, which was down 623.56% from -$1.6 million recorded in Q2 2025.
  • In the past 5 years, Pharma's EBITDA registered a high of -$1.2 million during Q1 2025, and its lowest value of -$6.7 million during Q1 2022.
  • Moreover, its 5-year median value for EBITDA was -$2.4 million (2024), whereas its average is -$2.8 million.
  • As far as peak fluctuations go, Pharma's EBITDA plummeted by 18541.25% in 2021, and later skyrocketed by 6684.62% in 2024.
  • Pharma's EBITDA (Quarter) stood at -$2.3 million in 2021, then dropped by 0.26% to -$2.3 million in 2022, then plummeted by 141.17% to -$5.6 million in 2023, then soared by 66.85% to -$1.8 million in 2024, then increased by 0.38% to -$1.8 million in 2025.
  • Its EBITDA stands at -$1.8 million for Q3 2025, versus -$1.6 million for Q2 2025 and -$1.2 million for Q1 2025.